REVIEW: γ-Secretase inhibitors for the treatment of Alzheimer's disease: The current state.

ABSTRACT:

Aims

Drugs currently used for the treatment of Alzheimer's disease (AD) partially stabilize patients' symptoms without modifying disease progression. Brain accumulation of oligomeric species of β-amyloid (Aβ) peptides, the principal components of senile plaques, is believed to play a crucial role in the development of AD. Based on this hypothesis, huge efforts are being spent to identify drugs able to interfere with proteases regulating Aβ formation from amyloid precursor protein (APP). This article briefly reviews the profile of γ-secretase inhibitors, compounds that inhibit γ-secretase, the pivotal enzyme that generates Aβ, and that have reached the clinic.

Discussion

Several classes of potent γ-secretase inhibitors have been designed and synthesized. Preclinical studies h

SUBMITTER: Panza F 

PROVIDER: S-EPMC6493789 | biostudies-literature | 2010 Oct

REPOSITORIES: biostudies-literature